Preferred Label : Polatuzumab Vedotin;
NCIt synonyms : ADC DCDS4501A; Antibody-Drug Conjugate DCDS4501A; polatuzumab vedotin-piiq;
NCIt definition : An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against
B-cell antigen receptor complex-associated protein beta chain (CD79B) conjugated,
via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin
derivative and a potent microtubule inhibitor, with potential antineoplastic activity.
Upon administration, the monoclonal antibody moiety of polatuzumab vedotin selectively
binds to CD79B, a protein which is abundantly expressed on the surface of B-cells.
Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits
its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. CD79B,
a component of the B-cell receptor (BCR), plays a key role in B-cell receptor signaling
and is expressed on the surface of almost all types of malignant B-cells.;
UNII : KG6VO684Z6;
CAS number : 1313206-42-6; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1313206-42-6
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Drug name : Polivy;
Molecule name : DCDS4501A; RG7596; Ro 5541077-000; FCU 2711;
Codes from synonyms : 93818;
Origin ID : C104153;
UMLS CUI : C4078806;
Currated CISMeF NLP mapping
- Manual BTNT mappings - CISMeF
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_target
- is_component_of_chemotherapy_regimen
